JP2020536531A - 免疫療法としてのｐｄ１特異的キメラ抗原受容体 - Google Patents

免疫療法としてのｐｄ１特異的キメラ抗原受容体 Download PDF

Info

Publication number
JP2020536531A
JP2020536531A JP2020518645A JP2020518645A JP2020536531A JP 2020536531 A JP2020536531 A JP 2020536531A JP 2020518645 A JP2020518645 A JP 2020518645A JP 2020518645 A JP2020518645 A JP 2020518645A JP 2020536531 A JP2020536531 A JP 2020536531A
Authority
JP
Japan
Prior art keywords
cells
domain
cell
chpd1
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020518645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536531A5 (OSRAM
Inventor
アモレット バーバー
アモレット バーバー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Longwood University
Original Assignee
Longwood University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Longwood University filed Critical Longwood University
Publication of JP2020536531A publication Critical patent/JP2020536531A/ja
Publication of JP2020536531A5 publication Critical patent/JP2020536531A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020518645A 2017-09-26 2018-09-26 免疫療法としてのｐｄ１特異的キメラ抗原受容体 Pending JP2020536531A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762563336P 2017-09-26 2017-09-26
US62/563,336 2017-09-26
PCT/US2018/052799 WO2019067504A1 (en) 2017-09-26 2018-09-26 SPECIFIC CHIMERIC ANTIGEN RECEPTOR AT PD-1 AS IMMUNOTHERAPY

Publications (2)

Publication Number Publication Date
JP2020536531A true JP2020536531A (ja) 2020-12-17
JP2020536531A5 JP2020536531A5 (OSRAM) 2021-09-30

Family

ID=65903543

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020518645A Pending JP2020536531A (ja) 2017-09-26 2018-09-26 免疫療法としてのｐｄ１特異的キメラ抗原受容体

Country Status (9)

Country Link
US (2) US11559549B2 (OSRAM)
EP (1) EP3688143A4 (OSRAM)
JP (1) JP2020536531A (OSRAM)
KR (1) KR20200070236A (OSRAM)
CN (1) CN111433354A (OSRAM)
AU (1) AU2018339528A1 (OSRAM)
CA (1) CA3077187A1 (OSRAM)
MX (1) MX2020007357A (OSRAM)
WO (1) WO2019067504A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016210129A1 (en) * 2015-06-23 2016-12-29 Memorial Sloan-Kettering Cancer Center Novel pd-1 immune modulating agents
AU2018339528A1 (en) 2017-09-26 2020-04-16 Longwood University PD1-specific chimeric antigen receptor as an immunotherapy
JP2023525049A (ja) * 2020-05-08 2023-06-14 シアトル・チルドレンズ・ホスピタル・ドゥーイング／ビジネス／アズ・シアトル・チルドレンズ・リサーチ・インスティテュート ナチュラルキラー細胞を標的とするキメラ抗原受容体（ｃａｒ）
CA3189671A1 (en) * 2020-07-17 2022-01-20 Instil Bio (Uk) Limited Receptors providing targeted costimulation for adoptive cell therapy
WO2022211376A1 (ko) * 2021-04-01 2022-10-06 주식회사 이뮤노로지컬디자이닝랩 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
KR20220144000A (ko) * 2021-04-16 2022-10-26 주식회사 이뮤노로지컬디자이닝랩 Programmed death-ligand 1(PD-L1)에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도
EP4444869A4 (en) * 2021-12-06 2026-01-07 Vycellix Inc CHIMERICAL SWITCHING RECEPTORS IN NK CELLS
JP2025522815A (ja) 2022-07-05 2025-07-17 ネオミクス ファーマシューティカルズ リミティド ライアビリティ カンパニー キメラ細胞内シグナル伝達ドメインに連結されたｂｃｍａナノボディを含むキメラ抗原受容体
CN118359727A (zh) * 2023-01-17 2024-07-19 上海以慈生物科技有限公司 突变的pd1胞外域片段及含有该片段的car和nk细胞
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106399255A (zh) * 2016-04-13 2017-02-15 李华顺 Pd-1 car-t细胞及其制备方法和应用
JP2017512484A (ja) * 2014-04-10 2017-05-25 シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート 特定の組成を有する遺伝子により改変されたｔ細胞製剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
PH12014500247A1 (en) * 2011-07-29 2014-03-24 Univ Pennsylvania Switch costimulatory receptors
CN106793780B (zh) * 2014-06-06 2020-05-26 蓝鸟生物公司 改善的t细胞组合物
SG11201700770PA (en) * 2014-08-19 2017-03-30 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
MX389823B (es) * 2014-10-27 2025-03-20 Fred Hutchinson Cancer Center Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
KR102133857B1 (ko) 2015-03-02 2020-07-20 이노베이티브 셀룰러 테라퓨틱스 코퍼레이션 리미티드 Ｐｄ－ｌ１에 의해 유도된 면역관용의 감소
CN106350533B (zh) * 2015-10-09 2020-07-17 上海宇研生物技术有限公司 Anti-PD-L1-CAR-T及其制备方法和应用
SG11201802966TA (en) * 2015-10-20 2018-05-30 Kite Pharma Inc Methods of preparing t cells for t cell therapy
IL320149A (en) * 2017-03-16 2025-06-01 Alpine Immune Sciences Inc Pd-l1 variant immunomodulatory proteins and uses thereof
AU2018339528A1 (en) 2017-09-26 2020-04-16 Longwood University PD1-specific chimeric antigen receptor as an immunotherapy
CN108384795A (zh) * 2017-10-13 2018-08-10 江苏西迪尔生物技术有限公司 作用于tme免疫效应细胞的人工合成基因及验证方法和应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017512484A (ja) * 2014-04-10 2017-05-25 シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート 特定の組成を有する遺伝子により改変されたｔ細胞製剤
CN106399255A (zh) * 2016-04-13 2017-02-15 李华顺 Pd-1 car-t细胞及其制备方法和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RES, vol. Vol.77, 13_Supplement, JPN7022003349, 1 July 2017 (2017-07-01), pages 4983, ISSN: 0005032557 *
CANCER RES., vol. 76, no. 6, JPN7022003350, 15 March 2016 (2016-03-15), pages 1578 - 1590, ISSN: 0005032558 *
DRUG DELIVERY SYSTEM, vol. 28, no. 1, JPN6023013830, 2013, pages 35 - 44, ISSN: 0005032559 *

Also Published As

Publication number Publication date
US20230293583A1 (en) 2023-09-21
KR20200070236A (ko) 2020-06-17
CN111433354A (zh) 2020-07-17
WO2019067504A1 (en) 2019-04-04
EP3688143A1 (en) 2020-08-05
AU2018339528A1 (en) 2020-04-16
US11559549B2 (en) 2023-01-24
CA3077187A1 (en) 2019-04-04
MX2020007357A (es) 2021-08-11
US20200281974A1 (en) 2020-09-10
EP3688143A4 (en) 2021-09-22

Similar Documents

Publication Publication Date Title
US20230293583A1 (en) Pd1-specific chimeric antigen receptor as an immunotherapy
JP7291396B2 (ja) 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
ES2966099T3 (es) Receptores de antígeno quiméricos dirigidos al antígeno de maduración de células B y usos de los mismos
CA2901960C (en) Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
CN113166226B (zh) 表达显性负性fas的免疫应答细胞及其用途
ES2963718T3 (es) Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
CA3162892A1 (en) Cd19 and cd22 chimeric antigen receptors and uses thereof
KR102612313B1 (ko) 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
JP7382829B2 (ja) キメラ抗原受容体を発現するｔ細胞
KR102823603B1 (ko) 면역요법을 위한 t 세포 수용체
KR20210020932A (ko) Bcma 키메라 항원 수용체 및 이의 용도
KR20200023165A (ko) 단일 도메인 항체에 기반한 bcma 키메라 항원 수용체 및 응용
KR20190129082A (ko) 고친화도 mage-a1-특이적 tcr 및 이의 용도
JP2023138960A (ja) キメラ抗原受容体を発現する免疫細胞
KR20150128997A (ko) 면역치료용 조성물 및 방법
IL297916A (en) Compositions and methods for tcr reprogramming using CD70-specific fusion proteins
JP7776414B2 (ja) Ｃｄ３７１を標的にする抗原認識受容体およびその使用
JP2023515707A (ja) Ｃｄ１９を標的とするキメラ抗原受容体およびその使用
CA3203180A1 (en) Compositions and methods for tcr reprogramming using fusion proteins
AU2020307688B2 (en) Combination cancer immunotherapy
EP4423283A1 (en) Chimeric adaptor polypeptides
CN115151274B (zh) Hla限制性hormad1 t细胞受体及其用途
WO2025096673A1 (en) Compositions comprising cells targeting cancer and methods of using the same
WO2026102195A1 (en) Chimeric tcr constructs targeting bcma and cd19 or cd20 and cd19, and uses of the same
CN119894923A (zh) 包含tmigd2共刺激结构域的嵌合抗原受体及其相关使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210823

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20211014

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20211015

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230410